TEVA.TA - Teva Pharmaceutical Industries Limited

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
8,640.00
-110.00 (-1.26%)
As of 12:03PM IDT. Market open.
Stock chart is not supported by your current browser
Previous Close8,750.00
Open8,646.00
Bid8,639.00 x 200
Ask8,640.00 x 34100
Day's Range8,636.00 - 8,679.00
52 Week Range3,820.00 - 11,850.00
Volume51,956
Avg. Volume632,150
Market Cap87.782B
Beta0.72
PE Ratio (TTM)N/A
EPS (TTM)-15.79
Earnings DateMay 9, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2017-11-28
1y Target Est19.50
  • Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical
    Market Realist5 days ago

    Analysts Raise Their 12-Month Target Price on Teva Pharmaceutical

    On June 11, Leerink raised its 12-month target price on Teva from $13 to $16 while maintaining its “underperform” rating on the stock. Leerink analyst Ami Fadia revised the target prices to better reflect the improving dynamics of the company.

  • Teva to Discontinue a Fremanezumab Study on Cluster Headache
    Zacks6 days ago

    Teva to Discontinue a Fremanezumab Study on Cluster Headache

    Teva decides to halt a phase III study, evaluating fremanezumab for the treatment of chronic cluster headache, following an interim analysis, which anticipates that the study is unlikely to meet its endpoint.

  • A Look at Teva’s Generic Drugs Research Pipeline
    Market Realist6 days ago

    A Look at Teva’s Generic Drugs Research Pipeline

    Teva Pharmaceutical Industries (TEVA) is the largest generics pharma manufacturer in the world. In particular, the FDA is approving generics versions of branded drugs more rapidly to shift toward a more affordable healthcare structure. Teva is on track to achieve targeted cost reductions and revenue growth.

  • Teva Scraps A Study In Cluster Headaches — And This Rival Benefits
    Investor's Business Daily8 days ago

    Teva Scraps A Study In Cluster Headaches — And This Rival Benefits

    Alder Biopharmaceuticals gapped up Friday after rival Teva Pharmaceutical scrapped a late-stage study in chronic cluster headaches.

  • Here's Why Alder Biopharmaceuticals Is Rising Today
    Motley Fool9 days ago

    Here's Why Alder Biopharmaceuticals Is Rising Today

    Traders cheer after a rival drug maker decides to partially scrap a late-stage study. Here's what investors need to know.

  • Teva’s Key Drugs in Its Specialty Products Pipeline
    Market Realist9 days ago

    Teva’s Key Drugs in Its Specialty Products Pipeline

    Teva Pharmaceutical’s (TEVA) fremanezumab is a key product awaiting FDA approval. The drug is also under Phase 2 trials for the treatment of post-traumatic headache and a Phase 3 trial for the treatment of cluster headache. The drug is expected to generate significant sales for the company in the years ahead. Teva’s specialty products pipeline is shown in the chart below.

  • Teva Stock Up ~27% YTD in 2018: What’s Driving the Stock Rally?
    Market Realist9 days ago

    Teva Stock Up ~27% YTD in 2018: What’s Driving the Stock Rally?

    On June 13, Teva Pharmaceutical Industries (TEVA) ended the trading day at a closing price of $24.33. TEVA stock was trading ~28.0% lower than its 52-week high of $33.80 reported on July 13, 2017. Currently, TEVA stock is trading higher than its 50-day moving average of $20.52 as well as its 200-day moving average of $19.05.

  • Reuters9 days ago

    Teva to discontinue study for chronic headache treatment

    Israel's Teva Pharmaceutical Inc said on Friday it would discontinue a trial testing its drug for the treatment of chronic cluster headache, after an analysis showed that the drug was unlikely to meet the study's main goal. Cluster headaches occur in cyclical patterns, or clusters, and are among the most painful types of headaches. The drug, fremanezumab, is under review by the U.S. Food and Drug Administration for prevention of migraines in adults and the company hopes to launch the drug for the disorder as soon as mid-September.

  • MarketWatch9 days ago

    Teva to end late-stage trial of chronic cluster headache treatment after disappointing results

    Shares of Teva Pharmaceutical Industries Ltd. dropped 1.4% in premarket trade Friday, after the drug maker said it will discontinue the phase 3 trial of its treatment for chronic cluster headaches, after ...

  • Business Wire9 days ago

    Teva Provides Update on Clinical Trial of Fremanezumab for Use in Chronic Cluster Headache

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced a change in the clinical development program of fremanezumab in chronic cluster headache. The ENFORCE Phase III clinical development program includes a chronic cluster headache study, an episodic cluster headache study, and a long-term safety study.

  • A Look at Teva Pharmaceutical’s Valuation Multiples in June
    Market Realist9 days ago

    A Look at Teva Pharmaceutical’s Valuation Multiples in June

    On June 13, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 8.8x, compared to the industry average PE of 12.3x. The company’s forward EV-to-EBITDA, which is a capital structure–neutral valuation measure, is 11.2x. This multiple is higher than the industry average of 10.3x.

  • Analysts’ Recommendations for Teva Pharmaceutical in June
    Market Realist9 days ago

    Analysts’ Recommendations for Teva Pharmaceutical in June

    Teva Pharmaceutical Industries (TEVA) has been in the news lately and is one of the most keenly watched stocks on Wall Street. Teva Pharmaceutical has reported positive developments with respect to its restructuring plan to restore its falling sales. On June 13, Reuters surveyed 29 analysts covering Teva.

  • Valeant Pharmaceuticals’ Valuation on June 8
    Market Realist13 days ago

    Valeant Pharmaceuticals’ Valuation on June 8

    As we discussed earlier, Valeant Pharmaceuticals (VRX) reported a non-GAAP EPS of $0.88 on revenues of ~$2.0 billion during the first quarter. Valeant had a 5.4% decline in its year-over-year revenues during the first quarter due to a 9% decrease in operating revenues. The decrease was partially offset by the favorable impact of foreign exchange—compared to revenues of ~$2.1 billion during the first quarter of 2017.

  • Teva Stock Could Jump after Good News from Partner Manufacturers
    Market Realist13 days ago

    Teva Stock Could Jump after Good News from Partner Manufacturers

    Eagle Pharmaceuticals (EGRX), a US-based drug maker and a partner of Teva Pharmaceutical that specializes in the development of critical care drugs, won a lawsuit against the US FDA. The FDA had refused to grant orphan drug status to Teva Pharmaceutical and Eagle Pharmaceuticals’ Bendeka (bendamustine hydrochloride) for the treatment of individuals with chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. The orphan drug status will grant Teva Pharmaceutical an extra seven years of patent protection and market exclusivity.

  • The Cheapest Drug Stocks to Buy Right Now
    Motley Fool13 days ago

    The Cheapest Drug Stocks to Buy Right Now

    All three of these bargains have forward P/E ratios of less than eight.

  • Should You Buy Teva Pharmaceutical Industries Limited (NYSE:TEVA) At $23.11?
    Simply Wall St.13 days ago

    Should You Buy Teva Pharmaceutical Industries Limited (NYSE:TEVA) At $23.11?

    Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw a significant share price rise of over 20% in the past couple of months on the NYSE. With many analysts covering the large-cap stock,Read More...

  • Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why
    Zacks26 days ago

    Teva (TEVA) Stock Up 17% YTD After a Dismal 2017: Here's Why

    Teva's (TEVA) shares gain 17% in 2018 so far after declining sharply in 2017.

  • Benzingalast month

    Benzinga's Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck's Cancer Drug Review Extended

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Here are the biotech stocks that were hitting 52-week highs May 24:  ArQule, Inc. (NASDAQ: ARQL ) Baxter ...

  • FDA Confirms September Action Date for Teva's Migraine Drug
    Zackslast month

    FDA Confirms September Action Date for Teva's Migraine Drug

    Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June.

  • Benzingalast month

    Jim Cramer Gives His Opinion On Blue Apron, Teva And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer advised his viewer to hold his long position in Sirius XM Holdings Inc (NASDAQ: SIRI ). He has been recommending the stock since $4 and he is ...

  • Reuterslast month

    Teva hopes to launch migraine drug as soon as September

    Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as soon as mid-September, after an initial delay. Teva and Eli Lilly are in a race to put a second migraine drug on the market, after rival Amgen won FDA approval last week for Aimovig to prevent migraine headaches in adults. Lilly has said it expects an FDA decision on its galcanezumab drug by the third quarter.

  • Reuterslast month

    Teva Pharm says FDA to decide on migraine drug on Sept 16

    Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday it could launch its migraine treatment as early as mid-September, after an initial delay. Teva had hoped to receive approval for the drug, ...

  • Business Wirelast month

    Teva Confirms September PDUFA Date for Fremanezumab

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed that the U.S. Food and Drug Administration (FDA) has extended the goal date of the Biologics License Application (BLA) for fremanezumab, an investigational therapy for the preventive treatment of migraine. The Prescription Drug User Fee Act (PDUFA) action date for fremanezumab is set for September 16, 2018.

  • Business Wirelast month

    CORRECTING and REPLACING Teva Announces Publication of Phase III Trial Data of Fremanezumab for the Preventive Treatment of Episodic Migraine in the Journal of the American Medical Association

    First bulleted paragraph, second sentence of release dated May 15, 2018 should contain the numbers 4.9, 5.3 and 6.5 . Third bulleted paragraph, second sentence, the first number should read 4.4 , and the final number should read 5.8 . Fourth paragraph, third sentence should read ...38.0, 41.7, and 37.3...

  • Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
    Zackslast month

    Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

    Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.